retatrutide phase 2 trial obesity nejm 2023 triple agonist Michael Weintraub, MD on X: "Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight Retatrutide vs Tirzepatide: Best Triple

Artificial chaperone-assisted refolding of carbonic anhydrase B

At the moment, Mounjaro is a diabetes drug, but Pisano said that the FDA is currently examining data on whether to include it in the weight loss class, and that decision might come in October

GPX4 is an antioxidant defence enzyme that can repair oxidative damage and is a major inhibitor of ferroptosis 26

L-Alanyl-Glutamine Attenuates Oxidative Stress in Liver Transplantation Patients

This contributes to the formation of microscopic blood clots, or microclots, which can physically block the tiny capillaries responsible for delivering oxygen to muscles and organs